Global Age-related Macular Degeneration (AMD) Drugs Market Size Study, by Product (Lucentis, Eylea & Eylea HD, Vabysmo, Syfovre), by Molecule (Ranibizumab, Aflibercept, Faricimab), by Approval Type (Biologic, Biosimilar), by Type of AMD, and Regional Fore

Global Age-related Macular Degeneration (AMD) Drugs Market Size Study, by Product (Lucentis, Eylea & Eylea HD, Vabysmo, Syfovre), by Molecule (Ranibizumab, Aflibercept, Faricimab), by Approval Type (Biologic, Biosimilar), by Type of AMD, and Regional Forecasts 2022-2032

The Global Age-related Macular Degeneration (AMD) Drugs Market is currently valued at approximately USD 9.45 billion in 2023 and is forecasted to grow at an impressive CAGR of 10.70% over the forecast period from 2024 to 2032. Age-related macular degeneration, a leading cause of vision impairment in aging populations worldwide, has propelled significant innovations in pharmacological interventions. Advanced treatments, such as biologics and biosimilars, are shaping a new era of therapeutic efficacy, focusing on slowing disease progression and improving patients' quality of life.

Pharmaceutical advancements like Lucentis, Eylea HD, and the novel Syfovre, alongside emerging biosimilars, are fueling the market's growth trajectory. The rise in patient awareness about early intervention and increasing healthcare expenditure in ophthalmology further amplify the demand for AMD therapies. Notably, the integration of personalized medicine into treatment protocols is a defining trend, offering tailored solutions that optimize therapeutic outcomes while minimizing adverse effects. Despite these advances, the high cost of biologic drugs and regulatory complexities surrounding biosimilar approvals may pose challenges to market participants during the forecast period.

Regionally, the AMD drugs market exhibits diverse growth dynamics. North America commands the largest market share, underpinned by robust healthcare infrastructure, high prevalence of AMD, and substantial investment in R&D initiatives. Europe follows closely, driven by strong government support and the adoption of advanced biologics. Meanwhile, the Asia-Pacific region is expected to record the fastest growth, attributed to increasing healthcare investments, rising geriatric populations, and enhanced access to ophthalmic care across emerging economies like China and India.

Major market players included in this report are:

1. Regeneron Pharmaceuticals, Inc.

2. Roche Holding AG

3. Novartis AG

4. Bayer AG

5. Biogen Inc.

6. Alimera Sciences

7. Adverum Biotechnologies, Inc.

8. Eyepoint Pharmaceuticals

9. Outlook Therapeutics, Inc.

10. Apellis Pharmaceuticals, Inc.

11. Amgen Inc.

12. Pfizer Inc.

13. Samsung Bioepis

14. Intas Pharmaceuticals

15. Santen Pharmaceutical Co., Ltd.

The detailed segments and sub-segments of the market are explained below:

By Product:
• Lucentis
• Eylea & Eylea HD
• Vabysmo
• Syfovre

By Molecule:
• Ranibizumab
• Aflibercept
• Faricimab

By Approval Type:
• Biologic
• Biosimilar

By Type of AMD:
• Wet AMD
• Dry AMD

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Years considered for the study are as follows:
• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032

Key Takeaways:
• Comprehensive revenue analysis and forecasts for a 10-year period (2022–2032).
• Detailed segmentation and regional insights for North America, Europe, APAC, Latin America, and MEA.
• Competitive landscape profiling major industry players with strategic recommendations for market expansion.
• Examination of emerging trends like biosimilar approvals and personalized medicine applications.
• Demand-side and supply-side assessments to identify growth opportunities and market challenges.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.